Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

RuiYi and Genor Enter License and Collaboration for Novel mAb

publication date: May 16, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
RuiYi Inc., a San Diego-Shanghai biotech startup, has signed an exclusive license and collaboration with Genor BioPharma to develop RuiYi’s lead molecule in China. The drug candidate, RYI-008, is a novel anti-IL-6 monoclonal antibody with potential to treat autoimmune diseases and cancer. Earlier this week, RuiYi announced that CMC Biologics would develop a cell line for RYI-008. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...